<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Exemplary clinical trials employing viral vector based vaccines in the context of Ebola vaccine development.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Study start</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>
      <italic>N</italic>
     </bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine and delivery</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Outcome</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT00374309</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Sept 2006</td>
    <td valign="top" align="left" rowspan="1" colspan="1">31</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Ad5</bold> IM
     <break/> 2 × 10
     <sup>9</sup> or 2 × 10
     <sup>10</sup> VP Antigen: GP EBOV and SUDV
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> - Antibody responses in 100% (SUDV GP) and 55% (EBOV GP) of subjects in the higher dose group- No significant induction of VNTs - T cell responses in 82% (SUDV GP) and 64% (EBOV GP) 
     <break/>
     <bold>Of note:</bold> Reduced immunogenicity in participants with pre-existing immunity against Ad5
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02326194</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Dec 2014</td>
    <td valign="top" align="left" rowspan="1" colspan="1">120</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Ad5</bold> IM
     <break/> 4 × 10
     <sup>10</sup> or 1.6 × 10
     <sup>11</sup> VP Antigen: GP EBOV (2014)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety</bold>: No serious adverse events. 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/>- Antibody responses in all but two participants (lower dose) and all (higher dose group) by d28 
     <break/>- Specific T cell responses (by ELISPOT and ICS); 
     <break/>
     <bold>Of note:</bold> high dose of Ad5 vector able to overcome negative effects of pre-existing immunity
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02575456</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase II</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Oct 2015</td>
    <td valign="top" align="left" rowspan="1" colspan="1">500</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Ad5</bold> IM
     <break/> 8 × 10
     <sup>10</sup> or 1.6 × 10
     <sup>11</sup> VP Antigen: GP EBOV (2014)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Results not yet publicly available</td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02269423; NCT02280408</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Oct 2014</td>
    <td valign="top" align="left" rowspan="1" colspan="1">78</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>VSV, attenuated</bold>
     <break/> one or two doses IM 1 × 10
     <sup>6</sup>, 2 × 10
     <sup>7</sup> and 1 × 10
     <sup>8</sup> PFU Antigen: GP EBOV (1995)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Mild adverse events, no cases of arthritis 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/>- Antibody titers in all participants by day 28 
     <break/>- Increased levels of total and VNTs upon delivery of higher doses
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02231866; NCT02240875</bold>
     <xref ref-type="table-fn" rid="TN1">
      <sup>*</sup>
     </xref>
     <bold>; NCT02267109</bold>
     <xref ref-type="table-fn" rid="TN1">
      <sup>*</sup>
     </xref>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Aug 2014–Aug 2017</td>
    <td valign="top" align="left" rowspan="1" colspan="1">325</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ChAd3, replication deficient</bold>
     <break/> Single dose IM 1 × 10
     <sup>10</sup>, 2.0 × 10
     <sup>10</sup>, 2.5 × 10
     <sup>10</sup>, 5 × 10
     <sup>10</sup>, 1 × 10
     <sup>11</sup>, 2.0 × 10
     <sup>11</sup> VP Antigen: GP EBOV (1976) ± GP SUDV (1977)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable safety profile, mild to moderate adverse events. 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/>- Antibody responses in almost all subjects; indications for durability (significant antibody titers detectable up to 48 weeks post vaccination) 
     <break/>- VNTs in some subjects 
     <break/>- Antigen-specific CD4
     <sup>+</sup> and CD8
     <sup>+</sup> T cells in some subjects 
     <break/>- Increased immune responses upon MVA boost
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02289027; NCT02344407</bold>
     <xref ref-type="table-fn" rid="TN2">
      <sup>**</sup>
     </xref>
     <bold>; (NCT02485301); (NCT02548078)</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I/II</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Oct 2014 
     <break/>- Nov 2015
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">5244</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>ChAd3, replication deficient</bold>
     <break/> Single dose IM 2.5 × 10
     <sup>10</sup>, 5 × 10
     <sup>10</sup>, 1 × 10
     <sup>11</sup> VP Antigen: GP EBOV (1976)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> NCT02289027: Acceptable safety profile NCT02344407: serious adverse events within 12 months after inj. in 8.0% (40/500) of participants (9.4% in rVSV-ZEBOV) 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/> NCT02289027 
     <break/>- Antibody responses peaked at d28 (51 μg/ml high dose group); still significantly over placebo at d180 (25.5 μg/ml) 
     <break/>- CD4
     <sup>+</sup> and CD8
     <sup>+</sup> T cell responses in 57% (28/49) and 67% NCT02344407 
     <break/>- Antibody responses in 70.8 and 63.5% of the participants at 1 and 12 months, respectively (83.7 and 79.5% for VSV-ZEBOV)
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02283099; NCT02296983; NCT02287480</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase I; Phase I/II</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Nov 2014</td>
    <td valign="top" align="left" rowspan="1" colspan="1">158</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>VSV, attenuated</bold>
     <break/> single dose IM 3 × 10
     <sup>5</sup>, 3 × 10
     <sup>6</sup>, 1 × 10
     <sup>7</sup>, 2 × 10
     <sup>7</sup>, 5 × 10
     <sup>7</sup> PFU Antigen: GP EBOV (1995)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Doses of 1 × 10
     <sup>7</sup> PFU or higher: 
     <break/>- Arthralgia in 22% (11/51) participants of Geneva cohort; arthritis confirmed in 9/ 11 cases; maculopapular rash in 27% (3/11) of these cases 
     <break/>- Self-limiting cases of arthritis in 3.4% (2/60) participants in Germany and Kenya cohort Dose of 3 × 10
     <sup>5</sup> PFU: 
     <break/>- Reduced adverse events in mild to moderate range with arthralgia in 23% (13/56) participants 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/>- Antibody responses in all subjects; persisted for 6 months 
     <break/>- Dose dep. VNTs in 85% (107/126) of vaccinees
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" colspan="3" rowspan="1">
     <bold>NCT02378753</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Phase II/III</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">March 2015</td>
    <td valign="top" align="left" rowspan="1" colspan="1">7651</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>VSV, attenuated</bold>
     <break/> single dose IM 2 × 10
     <sup>7</sup> PFU Antigen: GP EBOV (1995)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Safety:</bold>
     <break/> Acceptable, one serious adverse event 
     <break/>
     <bold>Immunogenicity:</bold>
     <break/>- Ring vaccination approach; 48 clusters (4,123 people) and 42 clusters (3528 people) randomly assigned to immediate and delayed vaccination (21 days later) 
     <break/>- No cases of Ebola virus disease with symptom onset at least 10 days after randomization (immediate vaccination), 16 cases from seven clusters (delayed vaccination) 100% vaccination efficacy
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>This table exclusively lists exemplary clinical trials discussed in the text. Ad5, Adenovirus 5; EBOV, Ebola virus; GP, Glycoprotein; ICS, intracellular staining; IM, intramuscular; N, number of study participants; PFU, Plaque Forming Unit; SUDV, Sudan virus; VNT, virus neutralization titers; VSV, vesicular stomatitis virus; VP, viral particles.</p>
  <fn id="TN1">
   <label>*</label>
   <p>Boost with MVA based vaccine evaluated;</p>
  </fn>
  <fn id="TN2">
   <label>**</label>
   <p>
    <italic>Direct comparison with rVSV-ZEBOV arm</italic>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
